Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06122077 · ClinicalTrials.gov registry record
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
A clinical trial of Lung Cancer (Diagnosis), sponsored by Freenome Holdings.
- Recruiting
- Registry status
- 20,000
- Enrollment target
- 20
- Study locations
NCT06122077: Recruiting study of Lung Cancer (Diagnosis), sponsored by Freenome Holdings.
NCT06122077 is a study of Lung Cancer (Diagnosis) that is actively recruiting participants, run by Freenome Holdings. The registered enrollment target is 20,000 participants, above the 1,249-participant average among 6 other Lung Cancer (Diagnosis) trials with a reported enrollment target (1501% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06122077, a study of Lung Cancer (Diagnosis), is actively recruiting participants, sponsored by Freenome Holdings.
- RECRUITING
- Registry status
- 20,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT).
Primary Outcome
Clinical performance of the Freenome Blood Test, including sensitivity and specificity, in detecting lung cancer in subjects with positive and negative lung cancer outcomes during a 12-month follow-up period
Conditions Studied
Interventions
- DIAGNOSTIC_TEST blood draw
Study Locations (20)
Florida
- Hillcrest Medical Research - DeLand
- Universal Axon Clinical Research - Doral
- I.H.S Health, LLC - Kissimmee
- United Medical Research - Port Orange
- Charter Research - The Villages
- Charter Research - Winter Park
Illinois
- University of Chicago - Chicago
- Walgreens - Deerfield
- Springfield Clinic, LLP - Springfield
Kansas
- Aton Health - Leawood
- Ascension Via Christi Wichita - Wichita
California
- Science 37 - Los Angeles
Connecticut
- Stamford Hospital - Stamford
Georgia
- SpeciCare, Inc - Gainesville
Maryland
- Ascension St. Agnes Hospital - Baltimore
Massachusetts
- Cape Cod Hospital - Hyannis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,000 participants |
| Start Date | 2023-11-28 |
| Est. Completion | 2027-06-15 |
What NCT06122077 shows while recruiting
NCT06122077 is an observational study that tracks outcomes without assigning an intervention. Its 20,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,249-participant average among 6 other Lung Cancer (Diagnosis) trials with a reported enrollment target (1501% higher).
The record links to 1 condition, with Lung Cancer (Diagnosis) appearing as the primary indexed condition, and to 1 intervention - of which blood draw is the first listed.
NCT06122077 names 20 study sites across 12 states, led by Florida, Illinois, Kansas.
Frequently Asked Questions
What is clinical trial NCT06122077 about?
NCT06122077 is a clinical study titled "Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening". The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT).
What is the current status of trial NCT06122077?
This trial is currently recruiting. The enrollment target is 20,000 participants. The study started on 2023-11-28. Estimated completion is 2027-06-15.
What conditions does trial NCT06122077 study?
This clinical trial studies the following conditions: Lung Cancer (Diagnosis).
What interventions are being tested in trial NCT06122077?
The interventions under investigation include: blood draw (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06122077?
This trial is sponsored by Freenome Holdings, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06122077 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer (Diagnosis)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
RECRUITING · NA
-
SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors
RECRUITING · NA
-
Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots
RECRUITING
-
Telehealth Collaborative Care Model (CoCM) in Lung Cancer
RECRUITING · NA
-
Evaluating the Implementation of a Comprehensive Multilevel Virtual Oncology Program Among Veterans Diagnosed With Lung, Colorectal, Prostate, and Breast Cancers in the US Department of Veterans Affairs
RECRUITING
-
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
- NCT00830557 · 20,000 participants
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
- NCT00900471 · 20,000 participants
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
- NCT02735707 · 20,000 participants · Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI